Head-to-head evidence
Cerebrolysin vs PM012
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Multi-target (ginsenoside) · full Alzheimer's Disease pipeline
Cerebrolysin
Developed by EVER Neuro Pharma (EVER Pharma)
NCT00911807 · Phase 2 · completed
This was a randomized, quadruple-blinded, three-arm trial with 217 patients, comparing Cerebrolysin plus donepezil, Cerebrolysin alone, and donepezil alone. The primary endpoint, change in ADAS-Cog+ at week 28, did not show a statistically significant difference among the groups (overall p=0.6348; pairwise comparisons all non-significant), so the study did not meet its primary cognitive endpoint. Although the design was strong, the null primary result limits the evidence to a moderate level.
PM012
Developed by Mediforum Ltd., Co. (earlier trial by VTBIO Co. Ltd.)
NCT05811000 · Phase 2/3 · status unknown
This trial randomized 312 patients with mild Alzheimer's disease to one of three PM012 doses or the standard treatment donepezil, using double-dummy blinding so neither patients nor assessors knew which treatment was given, with cognitive and daily-living scales as the co-primary measures at 12 weeks. No results are posted yet, so it isn't known whether PM012 performed comparably to or better than donepezil.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cerebrolysin's landscape · PM012's landscape